Zurich, Switzerland, and Barcelona, Spain, February 11, 2010: The fourth annual BIO-Europe Spring ^® partnering event is less than four weeks away, taking place on March 8–10, at the Barcelona International Convention Center (CCIB), Spain. Despite the turbulent economy, the event has seen a steady stream of registrations since BIO-Europe in November of last year. To date there are 1,311 delegates registered from 806 companies in 42 countries. EBD Group, the producer of BIO-Europe Spring, expects over 1,600 decision makers to attend. read more >>

Zurich, Switzerland and Barcelona, Spain – February 3, 2010: Leaders from the global biotechnology industry will gather for the 4th annual BIO-Europe Spring^® partnering conference in Barcelona, Spain, March 8–10 at the CCIB’s Convention Centre. The event will attract more than 1,500 executives from 1,000 companies representing over 40 countries who will engage in upwards of 7,500 one-to-one partnering meetings. read more >>

Carlsbad, CA; Zurich, Switzerland and Florham Park, NJ. – Sept. 16, 2009: EBD Group and Defined Health today announced the formation of an alliance that will help biopharmaceutical firms gain the insights they need to create and execute successful strategy. Under this agreement, Defined Health will fold its highly regarded Therapeutic Insight conference into EBD Group’s BIO-Europe Spring® and BioPharm America™ partnering conferences. These events will now feature a "Defined Health Therapeutic Insight Track" that will bring together a diversity of industry thought-leaders and clinicians to explore transformative growth issues in leading therapeutic categories such as oncology, pain, CNS, cardiovascular and metabolic diseases, COPD and platforms such as orphan diseases, biosimilars and next-generation biologicals. read more >>

BIO-Europe Spring® moves to Barcelona in March 2010 where Biocat, the BioRegion of Catalonia, promises to surprise business development executives with unexpected opportunities for projects, products and investments.

A long period of investment in Catalonia is today yielding the emergence of a biotechnology capability growing at a rapid rate of 20 new companies per year, and Monteserrat Vendrell, the CEO at Biocat, said “We have a momentum that will not be stopped by any financial crisis, and in fact is being stimulated by this crisis.” read more >>